Key Highlights

  • First-quarter 2026 revenue rose 116.8% to $11.1 million, with gross margin expanding to 48.0% from 21.2%, per the company's May 13, 2026 earnings release.
  • Cumulative SSi Mantra procedures reached 9,744 as of March 31, 2026, and had climbed to 12,375 by July 6, 2026, comfortably surpassing the 11,000 mark.
  • A 510(k) premarket notification, filed in December 2025 after abandoning a De Novo pathway, remains under FDA review; a June 2026 presentation points to fourth-quarter 2026 or first-quarter 2027 clearance.
  • Roughly 87% of 2025 revenue came from India, and Q1 2026 India revenue alone was $10.95 million of $11.1 million total, underscoring heavy geographic concentration.

SS Innovations (NASDAQ:SSII) International reported first-quarter 2026 revenue of $11.1 million, up 116.8% from a year earlier, as its SSi Mantra surgical robot extended its installed base in India and a handful of other markets. Cumulative procedures on the platform have since climbed past 12,000. The bigger question is whether a company still overwhelmingly dependent on one country, and still awaiting U.S. clearance, can turn that momentum into a durable global business.

A Niche Robotics Maker Suddenly Commands Wall Street's Attention

Surgical robotics has long been dominated by a small number of well-capitalized incumbents selling systems costing more than a million dollars apiece. SS Innovations International has built its story around the opposite premise: a modular robot designed in Gurugram, India, priced to reach hospitals established players have bypassed. That pitch gained visibility after the May 13, 2026 announcement that quarterly revenue had more than doubled alongside a widening margin and shrinking loss, coinciding with a milestone of more than 11,000 completed procedures on the SSi Mantra platform, since updated in later filings.

Inside the SSi Mantra: A Lower-Cost Approach to Robotic Surgery

SS Innovations designs, manufactures and sells the SSi Mantra system along with a companion instrument line branded SSi Mudra, supporting general, urological, gynecological, colorectal and cardiac procedures. Headquartered in Gurugram, India, with corporate domicile in Florida, the company traces its listing to a 2022 reverse merger with a shell then known as AVRA Medical Robotics, Inc., later renamed SS Innovations International, Inc. Its stock was uplisted from the over-the-counter market to the Nasdaq Capital Market effective April 25, 2025, per its Form 10-Q, where it trades as SSII. The company touts telesurgery capability, used for remote procedures spanning thousands of miles, as a differentiator alongside lower cost.

SS Innovations (SSII) Rides a 117% Revenue Surge and a Surgery Count Past 11,000

First-quarter 2026 results, filed May 13, 2026, showed revenue of $11,101,366, up from $5,120,610 a year earlier, a rise the company rounded to 117%. System sales rose 112.7% to $9.6 million, instrument sales rose 141.2% to $1.15 million, and warranty revenue rose 192.0%. Installations totaled 26 systems, up 73.3% from 15, lifting the cumulative installed base to 194 systems across 11 countries.

Cumulative procedures reached 9,744 as of March 31, 2026, versus 3,568 a year earlier, and kept climbing: a June 15, 2026 SEC filing put procedures at 11,270 as of May 31 across 210 systems in 12 countries, and a July 17 filing put the tally at 12,375 as of July 6, including 653 cardiac procedures, 178 telesurgeries and 225 pediatric surgeries. The 11,000-procedure threshold has therefore been verifiably surpassed.

Installations, Margins and Losses Are All Moving in the Same Direction

Gross margin expanded to 48.0% in the first quarter from 21.2% a year earlier, continuing an annual trend of 12.3% in 2023, 40.9% in 2024 and 46.0% in 2025, per the June 2026 presentation. Net loss narrowed to $3.58 million, or $0.02 per diluted share, from $5.68 million, or $0.03 per share, helped by lower expenses relative to revenue even as stock-based compensation rose to $3.14 million from $2.38 million.

Geographic concentration remains pronounced. India generated approximately $10.95 million of the $11.1 million in first-quarter revenue, per the 10-Q, while the June presentation put India's share of full-year 2025 revenue at approximately 87%. Management expects the non-India share to grow as approvals elsewhere take effect.

Cash Improved After an Insider-Backed Placement, But Debt Dependence Persists

The company ended the quarter with $15.98 million in cash, excluding restricted cash, up from $3.21 million at year-end, reflecting a private placement that closed March 6, 2026. That offering raised approximately $18.6 million from 5,774,839 shares, with roughly $5.2 million bought by directors and executives, including CEO Sudhir Srivastava, Vice Chairman Frederic Moll and director Tim Adams, and the rest from outside investors at $3.00 per share. Shares outstanding rose to 200,131,535 from 194,165,141.

Long-term debt was zero, but the company carried $11.16 million in bank overdrafts, secured partly by personal guarantees from Dr. Srivastava and Dr. Vishwajyoti P. Srivastava, plus a $28 million convertible note from affiliate Sushruta Private Limited, later converted to equity.

The Path to Washington and Brussels

Management's growth strategy centers on deepening penetration in India while pursuing approvals elsewhere and, eventually, the United States and European Union. An October 2, 2025 filing said the company pivoted from a De Novo submission to a 510(k) pathway after FDA discussions and a human factors study at Johns Hopkins Hospital, then submitted the 510(k) notification on December 5, 2025, covering general, urological, colorectal, gynecological and cardiac indications. No clearance has been granted; the June 2026 presentation described the file as under review, with clearance anticipated in the fourth quarter of 2026 or first quarter of 2027. The company is separately pursuing CE marking, anticipated in the fourth quarter of 2026. Neither approval is in hand.

Concentration, Related Parties and a Revolving Finance Chair

Several risks stand out. The Form 10-Q states there is substantial doubt about the company's ability to continue as a going concern within one year, citing reliance on related parties even after the March placement. It also discloses a network of entities in which Dr. Srivastava is the ultimate beneficial owner, several carrying recurring expense and prepaid balances. Deferred-payment system sales have produced $7.27 million in long-term, non-current receivables tied to Indian customer contracts, tying revenue to collections that may extend beyond a year. Insider ownership is concentrated, with Dr. Srivastava alone holding roughly 58.8% of shares outstanding. Finance leadership has also turned over quickly: a CFO resigned in January 2026, an internal appointee followed, and in July the company named a third CFO.

Outlook

The optimistic case rests on verified fundamentals: triple-digit revenue growth, expanding margin, a shrinking loss, zero long-term debt and a fast-growing procedure count supporting the low-cost positioning. The base case is that SS Innovations keeps scaling mainly within India while U.S. and European applications move through multi-quarter reviews of uncertain outcome. The downside case centers on going-concern language, near-total revenue dependence on one country, an extensive related-party network, deferred-payment receivables that stretch collection risk, and reliance on equity issuance to fund operations. None of this alone resolves whether SS Innovations can compete with larger, better-capitalized manufacturers.

Conclusion

SS Innovations International's (SSII) first-quarter 2026 results confirm a verifiable growth story: revenue nearly doubled, margins improved, and the SSi Mantra platform's cumulative procedure count moved well beyond 11,000. Whether that becomes a durable challenge to established robotic-surgery leaders depends on unresolved variables, chiefly pending U.S. and European regulatory decisions, continued reliance on India, and governance questions tied to related-party dependence and rapid finance-leadership turnover that investors should weigh alongside the growth numbers.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.